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EXPLORING THE METHYLATION STATUS OF RAI1 AND THE RAI1  
CONSENSUS BINDING SEQUENCE 
By Eri Kamura, B.S. 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2009 
 
Major Director: Dr. Sarah H. Elsea 
Associate Professor, Departments of Pediatrics and Human and Molecular Genetics 
 
Smith Magenis Syndrome (SMS) is a multiple congenital anomalies/ mental 
retardation disorder caused by deletion or mutation of the RAI1 gene on chromosome 
17p11.2.  The majority of patients with SMS phenotypes have a deletion or mutation of 
RAI1.  However, some patients have been observed with SMS-like phenotypes and yet 
have no deletions or mutations in the RAI1 gene. One possible explanation could be 
aberrant methylation of RAI1 since RAI1 is present and yet may be silenced.  In order to 
viii 
 
study this possibility, patient cell lines were treated with 5-Aza-2’-deoxycytidine.  RNA 
was extracted and real-time PCR was used to check the RAI1 expression status on the 
cells.  RAI1 is thought to be a transcription factor, but the DNA binding sequence is still 
unknown.  Sequences from ChIP-chip data were compared to identify a consensus 
sequence. One gene which contained this consensus sequence was the chemokine-like 
receptor-1 gene (CMKLR1), which was investigated by luciferase assay.  CMKLR1 
showed upregulation when co-transfected with RAI1.
  
 
 
 
 
 
 
Chapter 1: Literature Review of Smith-Magenis Syndrome 
and RAI1 
 
Introduction 
Smith-Magenis syndrome (SMS) [OMIM, #182290] is a multiple congenital anomalies 
and mental retardation disorder.  SMS is characterized by craniofacial and skeletal 
anomalies, such as brachycephaly and midface hypoplasia, mental retardation, obesity, 
distinctive behavioral phenotypes, including self-injurious behaviors, speech delay, and 
sleep disturbance due to an inverted pattern of melatonin secretion.  The incidence of 
SMS is estimated to be around 1:15,000 – 25,000 but is thought to be under diagnosed 
(8,9).  SMS is commonly associated with an interstitial deletion involving chromosome 
17p11.2 which spans ~3.7 Mb and includes the retinoic acid induced 1 (RAI1) gene.  
Although the majority of patients with SMS share a common sized deletion, there have 
been reports of patients with both smaller and larger deletions, along with patients that 
have a mutation of RAI1 (8,21).  
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Physical Features  
The phenotype of SMS becomes more pronounced and recognizable as individuals age 
(12).  Significantly decreased fetal movement in ~50% of pregnancies was noted in 
prenatal histories for infants born at term.  Craniofacial features that have been reported 
include brachycephaly, a broad face, frontal bossing, synophrys, hypertelorism, 
upslanting eyes, midface hypoplasia with a depressed nasal bridge, a tented upper lip 
(cupid’s bow upper lip), prognathism, and low-set or abnormally shaped ears. Short 
stature (<5
th
 percentile) is commonly observed in young SMS patients (~67%), but most 
resolve over time with individuals reaching the 10-25
th
 percentile by adulthood (7,20).  
Obesity is also common in teens and adult SMS patients.  Other skeletal anomalies 
include brachydactyly, scoliosis, fifth-finger clinodactyly, 2/3 toe syndactyly, elbow 
limitations, forearm abnormalities, and vertebral anomalies (7,8,10). Otolaryngological 
abnormalities such as chronic ear infections often associated with hearing loss, and a 
hoarse voice are also common in these patients (8).   Ophthalmologic anomalies are also 
present in  >60% of SMS patients, including myopia, strabismus, nystagmus, 
microcornea, cataracts, iris anomalies, and retinal detachment (often resulting from 
violent behaviors) (8). 
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Neurological and Behavioral Features 
Most SMS patients have mild-to-moderate mental retardation with developmental delay 
observed during childhood. Infantile hypotonia is common in these patients.  Patient IQs 
range between 20-78 with IQ decreasing as the child ages.   Many of these children have 
significant speech delay and motor delay, having better receptive language skills than 
expressive language skills.  Some neurological features include peripheral neuropathy, 
pes cavus or pes planus, an abnormal gait, hyperactivity, balance problems, and most 
characteristic of this syndrome is self-injurious behavior.  Self-injurious behaviors 
include head-banging, self-biting, polyembolokoilamania (insertion of objects into bodily 
orifices), and onychotillomania (pulling out fingernails and toenails) (10).  Other 
behavioral characteristics include attention seeking behavior, impulsivity, an upper body 
squeeze or “self-hugging”, temper tantrums, aggression, distraction, and disobedience (8).  
 
Sleep Disturbance  
The most characteristic finding of SMS is sleep disturbance and is reported in 75% - 
100% of patients (7).  Sleep disturbances in individuals with SMS include difficulty 
falling asleep, diminished REM sleep, reduced 24 -hour and night sleep, fragmented and 
shortened sleep cycles with frequent nocturnal and early-morning awakenings, and 
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excessive daytime sleepiness (8). These patients also have “sleep attacks” where they 
suddenly fall asleep during evening meal time (6).  These abnormal sleep patterns are due 
to an inverted circadian rhythm of melatonin. 
 
Melatonin and circadian rhythm 
Melatonin is a naturally occurring hormone secreted by the pineal gland under the 
influence of the suprachiasmatic nuclei (SCN) of the hypothalamus.  The circadian 
rhythm of melatonin secretion is endogenous; however, it is entrained by the light/dark 
pattern of light received from the retina to the SCN (17).  Melatonin plays an important 
role in the bioregulation of circadian rhythms, sleep, mood, reproduction, and aging.  
Concentrations of melatonin in the serum gradually increase from the onset of darkness 
and peaks around 2 am to 4 am, and then decreases as the night ends.  Potocki et al. 
(2000) conducted a study measuring urinary excretion of 6-sulphatoxymelatonin (aMT6s), 
the major metabolite of melatonin, showing SMS patients had abnormalities in the 
circadian rhythm of aMT6s (17).  This suggested that the disturbed sleep in these patients 
could be caused by aberrations in the production, secretion, distribution or metabolism of 
melatonin (17).  β1-adrenergic antagonist therapy has been reported to help reduce the 
sleep disturbances and improve behaviors (7).   De Leersnyder et al. (2001) also 
conducted a study to determine the circadian rhythm of melatonin in SMS patients.  The 
study found a phase shift in the circadian rhythm of melatonin in these patients in which 
melatonin onset was around 6 AM, peak time was around 12 PM, and offset of melatonin 
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was around 8 PM.   Normal melatonin onset is around 9 PM, peak time is around 3:30 
PM, and offset is around 6AM.  The study showed how the melatonin secretion in SMS 
patients is inverted compared to normal melatonin secretion patterns and suggests this 
could be correlated to behavior problems SMS patients have (6).  Tantrums, naps, and 
sleep attacks all could correlate to the patients being tired because of their peak in 
melatonin secretion during the day/evening time.  Also, hyperactivity and attention 
deficit could also be a result of the patients trying to fight the sleepiness induced by the 
high melatonin (6). 
 
RAI1 
Approximately 90% of reported SMS cases have a deletion of the 17p11.2 region, while 
10% have a mutation in the RAI1 gene.  Deletions of this region are caused by abnormal 
chromosomal recombination, which occurs in susceptible repeat-rich regions of the 
genome, including chromosome 17p11.2.  Chen et al. (1997) identified three low-copy 
number repeats flanking the SMS common deletion region, called SMS-REPs (4).  
Unequal meiotic crossovers mediated through nonallelic homologous recombination 
occur between the proximal and distal SMS REPs that were identified resulting in ~70% 
of the SMS deletion cases resulting in a common deletion of ~3.7Mb (8,18).  Slager et al. 
(2003) conducted a study where they looked at three individuals with strong clinical 
suspicions of SMS but were negative for the 17p11.2 deletion.  They sequenced three 
genes that localized to the SMS critical region; developmentally regulated GTP binding 
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protein 2 (DRG2), RAS dexamethasone-induced 1 (RASD1), and RAI1 and found 
mutations only in RAI1.  This study supports the idea that haploinsufficiency of RAI1 
leads to SMS (18,19,22). 
The primary RAI1 transcript (GenBank AY172136, AJ271790; NM_030665.3; 
NP_109590.3; OMIM*607642) consists of six exons which generate a ~8.5kb mRNA 
and a 1906 amino acid protein (8).  The protein contains a bipartite nuclear localization 
signal, polyglutamine and polyserine tracts, and a C-terminal plant homeodomain (PhD)/ 
zinc-finger domain which is similar to that in the trithorax family of nuclear proteins (Fig. 
1).  Amino-acid sequence motifs representing these four domains in RAI1 are similar to 
the transcription factor stromelysin-1 platelet-derived growth factor-responsive element-
binding protein, TCF20.  This transcription factor is involved in growth and 
neurobehavioral regulation and therefore suggests RAI1 might also be a transcription 
factor(1,2,8). 
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     a)  
 
      b) 
 
 
Fig. 1:  RAI1 structure. a) The genomic structure of RAI1 with six exons. The light color in exon III-VI show the coding 
exons.  b) Protein structure of RAI1 with a bipartite nuclear localization signal, polyglutamine and polyserine tracts, and a C-
terminal plant homeodomain (PhD)/ zinc-finger domain. 
Source: Elsea and Girirajan 2008 
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Chapter 2: Exploring the methylation status of RAI1 
 
Introduction 
Genomic DNA Methylation 
There are several epigenetic modifications of DNA in the mammalian genome that affect 
the transcription of genes.  One of the most important, and the focus in this study, is DNA 
methylation. DNA methylation is a mechanism that does not alter the gene product but 
affects when and where the gene is expressed (5).  DNA methylation in the promoter 
region of a gene is associated with silencing of that gene (13).  DNA methylation is now 
considered the main contributor to the stability of gene expression status (15).  There are 
two kinds of methylation, which are maintenance DNA methylation, and de novo 
methylation.  DNA methylation involves the addition of a methyl group to the number 
five carbon of the cytosine in a CpG dinucleotide.  In mammals, methylation is essential 
for normal development and also plays a key role in imprinting and X-chromosome 
inactivation.  The most common place for DNA methylation to occur in vertebrates is at 
5’-CpG-3’ dinucleotides or CpG islands.  A CpG island is defined as a region with at 
least 200 bp with a GC percentage of over 50% and an observed/expected CpG ratio 
greater than 60%.   However, most CpG island promoter regions are protected from 
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methylation which leads to an expressed gene, whereas CpG sites in non-coding or 
coding regions are often methylated which would lead to a silenced gene(5).  DNA 
methylation patterns in somatic cells are stably inherited due to the function of DNA 
methyltransferases.  These enzymes perform maintenance DNA methylation at 
hemimethylated CpG sites after DNA replication (11).  Genetic disorders such as Prader-
Willi syndrome and Angelman syndrome are results of altered genomic imprinting, in 
which DNA methylation plays an important role (11).  This suggests that it may be 
possible that altered DNA methylation also plays a role in Smith-Magenis syndrome. 
SMS-like patients 
In the Elsea lab, there is a cohort of patients (~75% of patients referred to the lab), 
referred to as “SMS-like”, that are clinically suspected to have Smith-Magenis syndrome 
but do not have a molecular diagnosis of SMS.  These patients have the classical clinical 
phenotypes of SMS, including craniofacial and neurological abnormalities, specifically 
self-injurious behaviors, hypotonia, and sleep disturbance but do not have a deletion of 
17p11.2 or a mutation of RAI1.  Previously, members of the Elsea lab have worked to 
provide evidence for the occurrence of RAI1 haploinsufficiency in patients with Smith-
Magenis syndrome.  RAI1 mRNA expression levels were measured using qRT-PCR 
using SMS patient lymphoblast cell lines and control lymphoblasts.  In the study, 7 out of 
17 “SMS-like” patients were found to have a lower expression of RAI1, even though they 
do not have a mutation or deletion of this gene (Fig. 2). (Lily Troung, Dissertation 2008) 
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Fig. 2  RAI1 expression in SMS and SMS-like patient cell line.  Mean results for each sample measured by real-time qRT-PCR and calibrated against 
SMS282 to obtain relative RAI1 mRNA expression levels (Ct ratio).  The relative mRNA expression level is numerically denoted above each sample.  
For each sample, real-time qRT-PCR measurements were performed in triplicate and repeated at least twice.     
Source: Lily Troung Dissertation 2008    
 
SMS-like RAI1 Mutation Normal Del(17)(p11.2) 
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The methylation status of the RAI1 gene has never been investigated, and aberrant 
methylation could be a likely explanation for the reduced RAI1 expression in the “SMS-
like” patients.  In order to investigate this issue, SMS patient cell lines were grown along 
with control cell lines and treated with 5-Aza-2’-deoxycytidine, a demethylating agent, 
and RAI1 expression was compared between the cell lines to identify any differences.   
Demethylating agents like 5-Aza-2’-deoxycytidine inhibit methylation by being 
incorporated into the nucleic acids of dividing cells where they act as inhibitors of DNA 
methyltransferases (DNMT), which catalyze the methylation reaction. This results in the 
expression of previously silenced genes (14).  Treatment with 5-Aza-2’-deoxycytidine 
that results in an increase in expression via real-time PCR suggests that DNA methylation 
at that locus could be responsible for downregulation of that gene. 
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Methods 
 
Cell Culture 
SMS patient cell lines (lymphoblasts) were taken from the frozen stock and thawed in a 
37°C for ~20 min.  RPMI with 10% FBS and 1% Pen/strep was also warmed in the 37°C 
water bath for ~20 min.  The cells in the cryovials were moved into a 25 cm
2 
cell culture 
flask along with 10 ml of warmed RPMI.  The cells were then maintained at 37°C in a 
CO2 incubator.  
 
Counting cells (lymphoblasts) 
Cells were grown for about 3 weeks depending on the growth rate of all the cells in the 
batch that was grown together.  Cells were harvested when it was determined that the 
slowest cell line had enough cells to seed them to a density of 500,000 cells per ml.  Cells 
were put in a 15 ml tube and centrifuged for 3 min at 12,000 rpm in a tabletop centrifuge.  
The supernatant was discarded and the cell pellet was resuspended in 5 ml of new RPMI 
with 10% FBS and 1% P/S.  This was then pipetted up and down in order to break up any 
cell clumps.  Cells were dyed with tryphan blue and counted using a hemocytometer.  
Cells were counted on the gridlines of the hemocytometer and the numbers were 
averaged to get a final cell count.  
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Splitting cells 
The cells were split to a density of 500,000 cells/ml.  They were split into three 25 cm
2
 
per cell line and labeled 0 M, 5 µM, 10 µM.  The cells were suspended in 5 ml of RPMI 
with 10% FBS and 1% P/S.  Cells were incubated at 37°C for 48 hrs.  Cells were grown 
in batches of about 3-4 cell lines which included control, RAI1 deletion, and “SMS-like” 
cell lines.  They were grown for approximately 3 weeks depending on how fast the RAI1 
deletion and “SMS-like” cell lines grew. 
 
5-Aza-2’-deoxycytidine treatment of cells 
After the initial 48 hr incubation after the cells were split, 2 ml of the old media were 
removed and replaced by 2 ml of fresh RPMI.  The cells were then treated with 5-Aza-2’-
deoxycytidine.  25 µl of 5-Aza was put in the flasks labeled 5 µM and 50 µl of 5-Aza was 
put in the flasks labeled 10 µM.  Cells were then incubated for another 48 hrs at 37°C.  
After the 48 hr incubation time, cells were put in a 10 ml tube and centrifuged for 3,min 
at 12000 rpm.  The supernatant was discarded, and cells were resuspended in 3 ml of PBS 
in order to get rid of any remaining residue of 5-Aza-2’-deoxycytidine.  The cells were 
then centrifuged again for 3 min at 12,000 rpm.  The supernatant was discarded, and the 
cells were resuspended in RPMI with FBS and P/S and put in a 25 cm
2 
cell culture flask 
and incubated at 37°C for 48 hrs. 
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RNA extraction 
After the 48 hr incubation period, RNA was extracted using the RNeasy mini kit 
(Qiagen) according to the manufacturer’s protocol.  An optional on-column DNase 
digestion was performed using the RNase-Free DNase set (Qiagen) according to the 
manufacturer’s protocol during the RNA purification process.  
 
Spectrophotometer 
RNA concentration was measured using spectrophotometry at 260 nm.  This was done in 
duplicates for each sample and the values were averaged to calculate the RNA 
concentration. 
 
Reverse transcriptase 
First-strand cDNA synthesis was performed using SuperScript™ II RT (Invitrogen) 
according to the manufacturer’s protocol.  The maximum amount of RNA was used by 
normalizing the RNA concentrations for each tube to the lowest concentration RNA.  The 
max amount of RNA from the lowest concentration RNA was added and the others were 
adjusted in order to add the same amount of RNA to the reaction.  Oligo(dT)12-18 (500 
µg/ml) was used and the optional RNase OUT (40 units/µl) was added. RNaseH (2 units) 
was then added after cDNA synthesis, and the reaction was incubated at 37°C for 20 min. 
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Real-time PCR 
Real-time PCR was performed on the AB7500 FAST system.  The master mix included 
Universal PCR Master Mix, No Amp Erase® UNG (Applied Biosystems), Taqman Gene 
expression Assay probes (ABI), and ddH2O.  The cDNAs prepared from the SMS patient 
cell lines were diluted 1:4 with ddH2O in order to minimize pipetting error.  A total 
volume of 6 µl of master mix and 4 µl of the diluted cDNA was added to each well on a 
96 well-plate. Samples were done in triplicates and normalized to an endogenous 
GAPDH.  The results are shown with Relative Quantification values (RQ) which take 
into account the endogenous GAPDH control and the calibrator.  The RQ values are 
automated calculations using the 7500 Fast PCR system (ABI).  The mean and SD were 
calculated for each study. 
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Results 
 
The methylation status of RAI1 was assessed by treatment of lymphoblast cell lines with 
5-Aza-2’-deoxycytidine.  Real-time PCR was used in this study to compare the RAI1 
expression levels for control lymphoblast cells and control cells treated with the 
demethylating agent.  The methylation status of the “SMS-like” cohort of patients was 
also investigated by comparing the expression levels of RAI1 between the patient cell 
lines and the 5-Aza-2’-deoxycytidine treated cell lines.  The lymphoblast cell lines were 
grown in batches to minimize the variability and included cases with 17p11.2 deletions, 
one or two “SMS-like”, and control controls, usually 3- 4 cell lines total per batch.  All 
samples were normalized with a GAPDH endogenous control probe in order to control 
for RNA sample variability and also normalized to a control cell line grown with each 
sample batch of cells in order to obtain relative expression levels (ΔΔCt ratio).  One 
major problem encountered while running these experiments is that the deletion cell lines 
and some “SMS-like” cell lines were very slow to grow and sometimes did not grow at 
all.  These were then discarded from the batch leaving the batch with one less cell line for 
evaluation and reducing the ability to compare expression levels.   
The data include all usable data from a total of 35 cell lines that were grown in batches.  
Cell lines were not included in the data if they did not grow, if the Ct values were higher 
than 30, or if the Ct std error was >0.2, since these results were too variable to analyze.  
All of the raw relative quantification (RQ) values shown are relative to one control line, 
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from the batch the individual cell lines were grown in, as a calibrator.  The RQ values 
were then combined into one graph as shown in the figures.  
 The results for RAI1 expression of control lymphoblast cell lines treated with 5-Aza-2’-
deoxycytidine are shown in Fig. 3.  The cell lines were not grown together, but were all 
calibrated to their own normal untreated cell line.  The trends are different between cell 
lines but for all the cell lines there is no difference between untreated cells and drug 
treated cell RAI1 expression.  No increase in RAI1 expression is observed comparing the 
5-Aza-2’-deoxycytidine treated cells to the untreated cells suggesting that RAI1 is not 
normally methylated.  Fig. 4 shows expression of RAI1 in RAI1 deletion patients relative 
to a control set as 1.  The cell lines are calibrated to the untreated control cell line in the 
batch they were grown in.  The results did not show lower expression in the RAI1 
deletion cell lines as was expected since deletion patients are haploinsufficient for RAI1. 
Instead RAI1 expression was as high as the controls.  Fig. 5 shows 5-Aza-2’-
deoxycytidine treated RAI1 deletion cell lines but they do not show a consistent change in 
expression. The cell lines are all calibrated to the untreated control cell line in the batch 
they were grown in.  Fig. 6 shows untreated “SMS-like” cell lines compared to the 
control.  In contrast to the preliminary data (performed by a previous student in the Elsea 
lab), they do not display a decreased expression compared to the controls. All cell lines 
were calibrated to the untreated control cell line from the batch they were grown in.  Fig. 
7 shows 5-Aza-2’-deoxycytidine treated “SMS-like” cell lines compared to the control.  
The results of expression change from the drug treatment differ from cell line to cell line 
and they are not consistent amongst themselves. There is no RAI1 expression increase 
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that can be observed comparing the demethylating agent treated cell lines to the untreated 
cell lines suggesting that methylation seems to not play a part in these “SMS-like” cell 
lines.  Fig. 8 shows the RAI1 expression of untreated control cell lines.  The study was 
repeated twice and the RQ values are calibrated to cell line 288.  The results show large 
variation in values even for the same cell lines.  Control cell lines are inconsistent and 
therefore suggests some other factor playing a role in RAI1 expression, like the timing of 
when RNA is extracted.  
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Fig. 3  RAI1 expression of 5-Aza-2’-deoxycytidine treated control cell lines.  Cell lines shown are all control 
cell lines which have been calibrated to the untreated line of each individual cell line.  All untreated control cell lines are 
shown as a raw RQ value of 1.  Study was performed twice and error bars represent the SD of the two experiments. Cell line 
211 does not have an error bar due to the fact it failed to grow during the repeat experiment.  Experiment was done twice and 
the qPCR was run in triplicate.  RQ values are caluculated by normalizing to GAPDH and calibrating to the control.
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Fig. 4  RAI1 expression of untreated RAI1 deletion cell lines.  Cell lines shown are RAI1 deletion cell lines with 
the raw RQ value determined by calibrating against the control cell line from the same batch.  There are no error bars due to 
the fact that these cell lines are extremely difficult to grow since they are slow in growth and often die before reaching the 
preferred density. RQ values shown are an average of triplicate wells from real-time PCR from a single study.  RQ values are 
caluculated by normalizing to GAPDH and calibrating to the control.
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Fig. 5  RAI1 expression of 5-Aza-2’-deoxycytidine treated RAI1 deletion cell lines.  Cell lines shown are 
RAI1 deletion cell lines treated with 5-Aza-2’-deoxycytidine.  RQ values are determined by calibrating against the control cell 
line from the same batches.  Error bars on the control treated lines are the SD of the 6 control cell lines.  The deletion cell lines 
have no error bars since they were only done once with qPCR done in triplicate.  RQ values are caluculated by normalizing to 
GAPDH and calibrating to the control.
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Fig. 6  RAI1 expression of untreated “SMS-like” cell lines.  Cell lines shown are all “SMS-like” patient cell lines 
which were calibrated against a control grown with the individual cell lines.  There are no error bars due to the fact the study 
was done once in triplicate.  RQ values are caluculated by normalizing to GAPDH and calibrating to the control. 
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Fig. 7  RAI1 expression of 5-Aza-2’-deoxycytidine treated “SMS-like” cell lines.  Cell lines shown are all 
“SMS-like” patient cell lines calibrated to their individual control controls in the same batches.  The error bars on the treated 
control cell lines represent the SD of the 6 control cell lines.  There are no error bars due to the fact they were done once and 
qPCR was done in triplicate.  RQ values are caluculated by normalizing to GAPDH and calibrating to the control. 
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Fig. 8  RAI1 expression of untreated control cell lines.  All cell lines shown are control cell lines calibrated to cell 
line 288.  Samples were evaluated twice in triplicate and the error bars show the SD of the mean of those two triplicate values.  
Cell line 211 does not have an error bar due to the fact that it failed to grow during the repeat study. Experiment was done 
twice and qPCR was done in triplicates each time.  RQ values are caluculated by normalizing to GAPDH and calibrating to the 
control.
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Discussion 
The methylation status of RAI1 has not been studied before.  In this study, the RAI1 
expression levels in control lymphoblast cells were compared to the expression of control 
lymphoblast cells that were treated with 5-Aza-2’-deoxycytidine.  If RAI1 was normally 
methylated, the gene expression after treatment with the demethylating agent should 
increase.  However, the results from this study showed no increase in RAI1 expression in 
these cell lines compared to the ones treated with 5-Aza.  This suggests that RAI1 is not 
normally methylated as was expected, as RAI1 is expressed in the population.   
The other part to this study was to investigate whether the reason behind the cohort of 
patients known as “SMS-like” having similar phenotypes as SMS patients was due to 
aberrant promoter methylation of RAI1.  The preliminary data did not have control cell 
lines grown with each RAI1 deletion and “SMS-like” cell line and therefore needed to be 
repeated.  RAI1 mRNA expression levels were measured by quantitative real-time PCR 
and compared with the same cell lines which were treated with 5-Aza-2’-deoxycytidine.  
The results of this study were not consistent with the q-PCR preliminary data (performed 
by a previous student in the Elsea lab). The range of the control cell lines were different 
and also the “SMS-like” cell lines and RAI1 deletion cell lines did not exhibit reduced 
RAI1 expression as previously shown.  The deletion cases and “SMS-like” cases did not 
have a decreased expression of RAI1.  RAI1 deletion patients are haploinsufficient and 
therefore should have a 50% reduced expression.  Differences in results compared to 
previous data may be due to the fact that RAI1 expression is sensitive to the growth 
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period and can differ depending on when the RNA is extracted.  The previous data may 
have lacked accuracy since this was not considered.  This problem was addressed by 
growing cells in batches so as to minimize environmental differences and length of 
growth.  A control cell line was always grown with a deletion cell line and “SMS-like” 
cell lines.  However, the deletion cell lines and some “SMS-like” cell lines have a slower 
doubling time, so the length of time they are grown is hard to control.  These cells were 
all started at the same time, harvested at the same time as soon as the slowest cell line 
grew enough to be seeded at the required density, RNA extraction was done at the same 
time, and reverse transcriptase was also done together.  However, cell densities were 
often not the same due to these differences in growth rates.  Since the data was 
inconsistent, the control cell lines were repeated to observe whether the RAI1 expression 
would be similar every time.  The results show that this is not the case and there is great 
variability in RAI1 expression even in biological repeats. Since the control data was also 
inconsistent, the method used for reverse transcriptase was investigated.  A comparison 
of RTs done with oligo dT, random primers, and both oligo dT and random primers 
revealed no differences (Fig. 9).  The conclusion from this experiment was that as long as 
the same method was used, ie. just oligo dT or just random primers, the outcome would 
not be different between cell lines.  Oligo dT was used for all real-time PCRs in the study 
as was in the preliminary study performed by a previous student.  Next, to check for 
technique errors in real-time PCR, cDNA prepared by the same individual was taken and 
a real-time PCR was run along with another individual using the same cDNA.  The 
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results again showed no difference between the two real-time PCR expression levels, and 
therefore real-time PCR technique error was ruled out (data not shown).  
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Fig. 9 RAI1 expression RT comparison.   Data shown are four different control lymphoblast cell lines.  There are no 
error bars due to the fact that the study was done once in triplicate.  RQ values are caluculated by normalizing to GAPDH and 
calibrating to the control.
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Chapter 3: Identification of the RAI1 consensus binding 
sequence: RAI1 regulates chemokine-like receptor 1 
 
 
Introduction 
Transcription factors are proteins that bind to specific DNA sequences and regulate 
transcription of other genes.  RAI1  is thought to be a transcription factor (8); however, it 
is still unknown which genes RAI1 regulates or to what DNA sequence it binds.  In order 
to identify genes that RAI1 regulates, other members in the Elsea lab conducted a ChIP-
chip experiment, which is a combination of chromatin immunoprecipitation and 
microarray technology on a genome wide scale.  This technique will identify regions of 
the genome where the RAI1 protein binds. The chip contains sequences that represent 
promoters and regulatory regions of known human genes.  An antibody to a Flag-tagged 
RAI1was used to pull down any chromatin sequence that bound RAI1 (or a protein bound 
to RAI1).  The acquired data were processed through the Signal Map program in order to 
narrow the putative RAI1 binding regions to the top ~200 candidates. Data from this 
study identified a large number of promoter sequences to which RAI1 was potentially 
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bound and thus, identified a cohort of genes that RAI1 may control.  Consensus 
sequences were identified by comparing the two shortest sequences from the top 
candidate genes obtained from the ChIP-chip study.  Potential target sequences were 
identified and functionality studies using luciferase assays were initiated. 
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Methods 
 
Chip-chip 
The Nimblegen standarad ChIP protocol was followed using the HG18 RefSeq promoter 
array.  The array has a 51 Mb coverage with 24,659 transcripts represented. Signal Map 
software was used to identify most likely hits. (done by Stephen Williams, data not 
shown) 
 
Identifying 5-7bp binding sequence 
In order to identify the RAI1 consensus binding region, the two shortest sequences from 
the top ChIP-chip candidate genes were chosen.  Microsoft Office Word was used to 
compare these two sequences by using the “ctrl find” function and taking the first 5 bases 
from the 1
st
 sequence and trying to find the consensus sequence in the 2
nd
 regulatory 
region sequence.  One base was shifted every time for a new search (Fig. 9).  About 25 
sequences of 5 ~7 bp in length were identified, and those sequences were then checked to 
determine if they were known transcription factor binding sequences using the program 
TESS and if they were present in the other gene promoter sequences in the ChIP-chip.  
The top 2 unique candidate binding sequences were chosen. 
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Amplifying putative binding region by PCR 
Primers were designed to amplify approximately 200 bp around the 5~7 bp sequence 
from genomic DNA.  PCR was conducted with the program set to 4min initial denaturing 
at 94°C, denature for 1 min at 94°C, and 35 cycles of 1 min annealing at temperature 
according to different primers, and extension for 30 sec at 72°C, followed by a final 
extension for 10 min at 72°C.  
Primer Sequences for CMKLR1: (334 bp) 
Forward – TAGTCATGTAGGATGCCA  
Reverse - ATGCTGTGCTCTAGAGACA 
 
Taq treatment 
10 µl of gel extracted product was combined with 0.25 µl Taq (5 U/µl) and incubated at 
72°C for 10 min.  This was done to ensure the As were still on the end of the PCR 
products for optimal cloning into the TA vector. 
 
Cloning 
The amplified PCR products were TOPO cloned into the TOPO2.1 vector according to 
the manufacturer’s protocol (Invitrogen).  PCR product that was Taq treated was used.  
The TOPO cloned product was then transformed into E.Coli cells by adding 2 µl of the 
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ligated product to 30 µl of One-shot chemically competent cells (Invitrogen) and 
incubated on ice for 30 min.  Then the cells were heat shocked at 42°C for 30 sec.  They 
were then immediately transferred to ice and 250 µl of S.O.C. medium was added.  The 
tube was then shaken horizontally at 37°C for 1 hr.  After the incubation, 40 µl was 
spread onto pre-warmed 50 µg/ml kanamycin plates.  Colonies were grown and DNA 
was prepared by standard methods (Fermentas). Once the insert was confirmed, the 
purified DNA was cut with KpnI and XhoI for ligation into the pGL3 promoter vector. 
 
Ligation into pGL3 
The concentration of CMKLR1 sequence in the TOPO plasmid was evaluated by the 
spectrophotometer. The following equation was used to determine the amount of insert 
and vector to add to the reaction. Ligation and transformation were carried out according 
to manufacturer’s protocol (Promega). 
 
 
Maxi-prep 
The pGL3 promoter vector with the CMKLR1 insert was maxi-prep’d for transfection. 
The Qiagen plasmid purification protocol was followed, starting with inoculating 100 ml 
medium. Cells were harvested, and the protocol for high-copy plasmids was used. The re-
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centrifugation step to remove the supernatant containing plasmid DNA was substituted 
by filtering the supernatant from the step before through a Whatman filter 3 by gravity 
flow. Subsequent steps were carried out as written in the protocol (Qiagen). 
 
Growing cells (HEK293 cells) 
Cells were grown in DMEM with 10% FBS and 1% Pen/Strep and maintained at 37°C in 
a CO
2 
incubator. 
 
Count cells (fibroblasts) 
Cells were washed with 5 ml of PBS then treated with trypsin for 5 min at 37°C.  The 
sides of the flask ware tapped to ensure all cells come off bottom of the flask.  5 ml of 
DMEM with 10%FBS was added to inactivate the trypsin.  Cells were cetrifuged at 
12,000 rpm for 2 min to form a pellet.  The cell pellet was resuspended in DMEM with 
FBS w/o P/S and counted using a hemocytometer. Cells (HEK293) were seeded at a 
density of 1.6x10
5
 cells in 2 ml of growth medium (DMEM w/FBS –P/S) in a 6-well 
plate. 
Transfection 
The Invitrogen lipofectamine™ reagent protocol was used. The transfection procedures 
were followed after scaling up for a 6-well plate. The cells were transfected with 1) 
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CMKLR1, RAI1, and β-galactosidase, 2) CMKLR1 and β -gal, 3) RAI1 and β -gal, and 4) 
with just β -gal by lipofection using Lipofectamine™ (Invitrogen) according to 
manufacturer’s protocol. DNA (2 µg) was put in 100 ml of OptiMEM (Invitrogen) and 
mixed with 25 µl lipofectamine reagent diluted in 100 µl OptiMEM (Invitrogen). The 
mixture was incubated at room temperature for 40 min to allow complexes to form. The 
complexes were then added to the HEK293 cells and incubated for 24 hrs at 37°C in a 
CO2 incubator. Following transfection, cells were washed twice with PBS, then treated 
with lysis buffer and cells were scraped off into a micro-centrifuge tube. They were then 
centrifuged and the supernatant was collected.   
 
Luminometer 
Cell lysate (50µl) was placed into a 96-well plate and the lipofectamine reagent protocol 
(Invitrogen) was followed along with the Galacto-Light System protocol (Applied 
Biosystems). 
 
Data analysis 
The data were analyzed by taking the value from the luciferase and dividing that by the 
value from the β-galactosidase. The CMKLR1+ RAI1 was set as 1 and the other values 
were divided by the CMKLR1+RAI1 value.  The mean and SD were calculated for each 
study. 
36 
 
 
Results 
 
Putative RAI1 consensus DNA binding sequence 
 
The ChIP-chip data revealed ~200 candidate gene promoters that bound RAI1 (or a 
protein bound to RAI1).  From the top ~200 genes, a 5~7 bp sequence was chosen via the 
method listed above (Fig.10).  The sequences that were most prevelant among the 
top~200 candidate genes were chosen with the sequences TGAATTT and AGAATAT.  
Variations of these two sequences; TGAAT, TGAATT, TGAATTT, AGAAT, AGAATA, 
and AGAATAT were checked in the top 100 candidate genes for their prevelance.  The 
results revealed that the three variations of the sequence TGAATTT appeared in 74% of 
the top 100 genes, and the three variations of the sequence AGAATAT appeared in 77% 
of the top 100 genes.  
From these sequences, the top candidate genes that were deemed to be relevant to Smith-
Magenis syndrome were selected to try and identify genes that RAI1 had a direct effect 
on.  The genes that were chosen for cloning were bone morphagenic protein 5 (BMP-5), 
minichromosome maintenance protein 10 (MCM10), zinc finger protein 545 (ZNF545), 
and beta-defensin 112 precursor (DEFB-12).  While amplifying these potential RAI1 
binding regions in the top candidate genes, DNA sequencing results of one of the genes 
revealed a completely different gene, than the sequence that was expected originally. 
Although this gene was not the gene the primers were designed for, it turned out to be the 
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Chemokine-like receptor-1 gene (CMKLR1). The gene was then checked on the array 
data to see if it was included in the top 200 candidate genes, and it was. This sequence 
was then checked to see if the 5~7 bp potential binding sequence was included and was 
found to have the AGAATT sequence in three places (Fig. 11).  Since the sequence 
amplified was in intron 2 of CMKLR1 and could be in a enhancer regulatory region, the 
CMKLR1 sequence was further studied to analyze whether or not RAI1 had an effect on 
its expression.  The other candidate gene sequences were not able to be cloned into pGL3 
due to wrong sequences, failure to PCR amplify, and unable to transfer into pGL3 from 
the TOPO vector.    
A luciferase assay was conducted by co-transfection of RAI1 and CMKLR1 regulatory 
region sequence.  The CMKLR1 sequence (Fig. 11) was put into a pGL3 vector that 
contained the luciferase gene and an SV40 promoter, and β-galactosidase was used as a 
control.  The relative light units were measured and compared with HEK293 cells that 
were transfected with 1) CMKLR1 regulatory region and β-galactosidase, 2) CMKLR1 
regulatory region + β-galactosidase + RAI1, 3) RAI1 and β-galactosidase, and 4) β-
galactosidase alone.  This experiment was done twice, each done in duplicate (Fig. 12). 
The results show an increase in relative light units when CMKLR1 regulatory region is 
co-transfected with RAI1.  However, when a confirmation was done to confirm the 
presence of this gene on the array it was found that the gene that existed on the array was 
the chemokine receptor like-1 gene (CCRL1) and not chemokine-like receptor-1 
(CMKLR1).  Also checking the array that was used in the ChIP-chip revealed that the 
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CMKLR1 gene was not present on the array and therefore would not have appeared in the 
ChIP-chip data.  Thus, studies were continued on the CMKLR1 gene.  
An additional transfection was done with RAI1 isoform-C to observe any fold change 
differences due to the fact that this isoform lacks a NLS(nuclear localization signal) and a 
PHD domain, which is thought to be the main binding domain for RAI1.  The luciferase 
activity was expected to stay the same as the controls and not increase since it lacks the 
NLS and the PHD domain.  The results show that the RAI1 isoform-C transfection with 
CMKLR1 regulatory region sequence reveals increased luciferase activity compared to 
the control but has decreased activity when compared to the full length RAI1 co-
transfection.
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chr11:55698469-55698721 
 
AAATCTCAGAAAAATGTATTAACTGATTGCATTTTTAAGTGAACAGTAAGAAAACGGAGATGGACATGAGCATTTTAAGCAAGCCCATC
CCTTAAAAATTTTTCCGTCTTTGGTAAGTTTTATTCATTCATTTGAATATTTATTTTTTCATATTTAGCATTCATTCTGCAGGTAATTGAAA
TTTTCAGTTAGATAAAATCCTTAAGGTTTTGAATCTTAAATTTTCTGTAAGTTAACACTGTGCCTTATTATG 
 
chr19:41562918-41563180 
 
GAGAGGTCTGTCTCCAATGAGACTGAATTTGTCCTGTCCTGCGTTCCTTCAGGAAAGAAATGGGATAAGCCCACCAGGGACCACCCT
GAGGCATCTTCTGTATCCCAAATTCTTTGATATATTAGTTAATACATGAAAGAATTTGTTCTTTCCTTAAGAATATAAAACTTTAGAAGAT
ATTTGAAAATGCCTCGGCAATCTGGTTTCATTTTGCAAACAATAGGATATGCATGAAATAGGAGATAAATGAAAAATCTGAGCTA 
 
 
 
Fig. 10  Identifying the 5~7 bp RAI1 binding sequences.  The two sequences shown are the two shortest sequences 
from the top candidate genes given by the ChIP-chip results.  The highlighted/underlined/italicized sequences are the matching 
sequences in both regulatory region. 
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chr12:107,223,494-107,223,656 
GCCGCCAGTGTGATGGATATCTGCAGAATTCGCCCTTATGCTGTGCTCTAGAGACACCTCCAGATCCCTGTATCC
CCAGGCTCTGACAGACTCGGGAACCTGGAAACCACACAGTGTCTGCAGATGTTCCAGCCACAGGCCTGGCTGCC
AGCCCCAGGACAGAATTAGCTCCGTGTCAGGAGAGAATTTCCTCCCTGGTCCCACGCC 
 
Fig. 11  Amplified CMKLR1 putative binding region sequence.  The highlighted sequences are the putative RAI1 binding 
sequences. 
 
41 
 
C
M
K
LR
1 
+ 
B
-g
al
C
M
K
LR
1 
+ 
B
-g
al
 +
 R
A
I1
R
A
I1
 +
 B
-g
al
B
-g
al
0.0
0.1
0.2
0.3
0.4
0.5
F
o
ld
  
C
h
a
n
g
e
 
Fig. 12  RAI1 co-transfection with CMKLR1 regulatory region.  Results shown are from two experiments done 
in duplicate. Error bars indicate SD (N=4). 
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Fig. 13 RAI1 isoform-C co-transfection with CMKLR1 regulatory region.  Results shown are from one 
experiment done in duplicate. Error bars indicate SD (N=2).
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Discussion 
Based on these studies, a gene potentially regulated by RAI1 is the chemokine-like 
receptor-1 gene (CMKLR1) [OMIM, #602351], also known as ChemR23, DEZ, 
MGC126105, or MGC126106 (Fig. 13).  CMKLR1 is a G-protein-coupled receptor which 
functions in skeletal system development, chemotaxis, immune response, and the G-
protein coupled receptor protein signaling pathway, and may also be associated with 
obesity and the metabolic syndrome (3).  Chemerin (TIG2), an adipokine which, upon 
proteolytic cleavage is able to activate CMKLR1, is the endogenous ligand for CMKLR1 
(16).  Bozagolu et al. (2007) conducted a study in which they found both chemerin and 
CMKLR1 expression to be elevated in adipose tissue (3,16). When the chemerin gene 
expression was compared in normal and type 2 diabetic P.obesus, it showed that 
chemerin was elevated in the obese animals and associated with the characteristics of 
metabolic syndrome (3).  In another study conducted by Martensson et al. (2005), it was 
shown that the expression of chemerin and CMKLR1 is induced by all trans retinoic acid 
(ATRA) from a luciferase reporter gene assay using ATRA stimulated cells; however, the 
study failed to identify any RA-responsive element (16).  Since chemerin and CMKLR1 
are both induced by RA, we hypothesized that RAI1 may be playing a role in regulating 
CMKLR1. This would be a reasonable hypothesis since one of the classic characteristics 
of Smith-Magenis syndrome is obesity.   
Although this was not the gene we expected to amplify, when we conducted a search on 
the CMKLR1 sequence we amplified, we found the 6 bp consensus sequence (AGAATT) 
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in 3 different places within the sequences and decided to further investigate the potential 
effect of RAI1 on its expression (Fig. 12).  In order to investigate whether RAI1 was 
directly playing a role in the expression of CMKLR1, we conducted a co-transfection of 
RAI1 and a fragment of the CMKLR1 gene containing the 6 bp potential binding 
sequence cloned into the pGL3-promoter vector and conducted a luciferase assay to 
evaluate the luciferase activity.  The luciferase assay was done by co-transfecting RAI1 in 
pDest26 (Invitrogen) and CMKLR1 in pGL3 (Invitrogen), which contains an SV40 
promoter upstream of the luciferase gene.  We expected to see an increase in expression 
of CMKLR1 compared to a control transfection if RAI1 was binding to the CMKLR1 
sequence and had a direct effect on CMKLR1 expression.  The results from the luciferase 
assay show an increased activity of luciferase when it was co-transfected with RAI1, 
compared to the control transfections (Fig. 12).  This suggests that RAI1 is directly 
binding to the CMKLR1 regulatory region and is enhancing the expression of CMKLR1 
or acting as a coactivator not directly bound.   
Additionaly, a co-transfection was done with the CMKLR1 sequence in pGL3 and RAI1 
isoform C in GFP.  The RAI1 isoform C has 964 amino acids and lacks a NLS and PHD 
domain.  The results from this transfection show that the RAI isoform-C transfection still 
shows increased luciferase activity.  This suggests that the RAI1 isoform-C is still getting 
into the nucleus probably due to effects of transfection and also that the PHD domain, 
which was thought to be the main DNA binding domain for RAI1, is not the only DNA 
binding domain.  The RAI1 isoform-C may be binding via the Poly-Q domain, Poly-S 
domain or another domain that is still unknown.  RAI1 could also be acting non-directly.
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Fig. 14 CMKLR1 gene structure. There are 3 exons with the last exon being a coding exon. The red box in intron 2 
represents the location of the potential regulatory region sequence that was amplified and inserted into pGL3.
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Chapter 4: Discussion 
 
 
Exploring the Methylation Status of RAI1 
The goal of this study was to investigate the methylation status of normal RAI1 and also 
whether “SMS-like” patients had aberrant promoter methylation that was causing RAI1 
expression to be reduced.  From the study in Chapter 2, by treating the cells with a 
demethylating agent, 5-Aza-2’-deoxycytidine, no increase in expression was observed in 
control cell lines compared with non-drug treated cells.  However, when “SMS-like” 
patient cell lines were investigated for RAI1 expression, the study revealed no decrease in 
RAI1 expression.  To further investigate the reason for the inconsistent data, a technique 
check was done on both reverse transcriptase and real-time PCR.  Both revealed no 
problem in the techniques.  The fact that the expression of RAI1 looks different in the 
data obtained from this study and the previous study may be due to the previous study 
combining all cell line data from different experiments; cells were grown and RNA and 
cDNA prepared at different times. .  All possible trouble shooting was done, but this 
project may need to be repeated in different cell types since the lymphoblastoid cells did 
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not give consistent expression results.  Future studies for this project include repeating 
the RAI1 deletion cell line treatment and “SMS-like” cell line treatements since these 
were only performed once. Also, conditions of the 5-Aza-2’-deoxycytidine treatment can 
be tested by also looking at a gene known to be methylated.  Another project would be to 
synchronize the cells by serum starvation to observe any differences in RAI1 expression 
during different times in the cell cycle.  Since lymphoblastoid cells are transformed cells, 
it is still unknown and studies still have not shown as to whether these are the optimal 
cells to investigate methylation on. At this point a conclusion can not be made accurately 
since some cell lines were only performed once, however, preliminarily the results seem 
to suggest that aberrant RAI1 methylation does not play a role in contributing to SMS-like 
patients.  In the future, if the RAI1 promoter region is sequenced and cloned, bisulfate 
sequencing or methylation specific PCR is another way to detect promoter methylation in 
this gene. 
 
RAI1 Consensus Binding Sequence 
RAI1 is thought to be a transcription factor but nothing about its binding or function is 
known. The project in Chapter 3 aimed to find a consensus binding sequence by 
comparing the data sequences obtained from another lab member’s ChIP-chip study.  The 
comparison of the sequences revealed 2 distinct sequences (and their variations) in ~75% 
of the top 100 gene candidates given by the ChIP-chip study.  A gene accidently found 
from this experiment is the chemokine-like receptor-1 (CMKLR1).  This gene was 
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accidently amplified but still contained the consensus sequence and also showed an 
increase in expression when co-transfected with RAI1.  The results from this study reveal 
an interesting relation of CMKLR1 and RAI1, thus further studies should be done to 
investigate its properties and interactions with RAI1.   
Future studies for this project include repeating the RAI1 isoform-C luciferase assay, and 
also conduct a RAI1 dosage response luciferase assay by varying the amount of RAI1 
added.  Future studies to investigate the exact RAI1 binding sequence should use site 
directed mutagenesis.  The 6 bp sequence in the CMKLR1 binding sequence could be 
mutated and transfection would be repeated to compare results with the transfection with 
the correct 6 bp binding sequence.  If the expression decreases, this might be an 
indication that the 6 bp potential binding sequence is correct.  If the expression still 
remains elevated, deletion constructs could be made by shortening either side of the 
CMKLR1 sequence and repeating transfections with the deletion constructs until a 
decrease in expression is found. An experiment that can be done to find direct evidence 
of RAI1 binding could be to perform a electrophoretic mobility shift assay (EMSA).  
This would show a band shift if RAI1 binds to the CMKLR1 sequence compared to a 
band that contains only DNA and would support the direct binding of RAI1 and 
CMKLR1. 
For some future studies regarding the CMKLR1 gene, real-time PCR experiments can be 
done to assess CMKLR1 expression in human adipose tissue obtained from liposuction.  
The expression of CMKLR1 will be compared to the expression level of CMKLR1 in 
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adipose tissue of subjects that are not overweight or obese.  This study can also be done 
in mice by assessing Cmklr1 expression in mouse adipose tissue from RAI1 transgenic, 
RAI1 knockout, and non-transgenic mice.  This study would show whether Cmklr1 
expression is really elevated in the adipose tissue and whether there is a difference in 
Cmklr1 expression in obese mice versus lean mice.  
Some other studies are using the co-transfected cells with RAI1 and the CMKLR1 
sequence and looking at CMKLR1 expression via real-time qPCR.  This study would 
show whether the expression if CMKLR1 is increased in the cells co-transfected with 
RAI1 versus cells that have just CMKLR1.  Increased expression levels of CMKLR1 
would be expected in obese individuals in humans, and increase expression of Cmklr1 
would be expected in RAI1 knockout mice since they are also obese.  
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